» Articles » PMID: 30521885

RNA Therapy: Are We Using the Right Molecules?

Overview
Journal Pharmacol Ther
Specialty Pharmacology
Date 2018 Dec 7
PMID 30521885
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Small-molecule and protein/antibody drugs mainly act on genome-derived proteins to exert pharmacological effects. RNA based therapies hold the promise to expand the range of druggable targets from proteins to RNAs and the genome, as evidenced by several RNA drugs approved for clinical practice and many others under active trials. While chemo-engineered RNA mimics have found their success in marketed drugs and continue dominating basic research and drug development, these molecules are usually conjugated with extensive and various modifications. This makes them completely different from cellular RNAs transcribed from the genome that usually consist of unmodified ribonucleotides or just contain a few posttranscriptional modifications. The use of synthetic RNA mimics for RNA research and drug development is also in contrast with the ultimate success of protein research and therapy utilizing biologic or recombinant proteins produced and folded in living cells instead of polypeptides or proteins synthesized in vitro. Indeed, efforts have been made recently to develop RNA bioengineering technologies for cost-effective and large-scale production of biologic RNA molecules that may better capture the structures, functions, and safety profiles of natural RNAs. In this article, we provide an overview on RNA therapeutics for the treatment of human diseases via RNA interference mechanisms. By illustrating the structural differences between natural RNAs and chemo-engineered RNA mimics, we focus on discussion of a novel class of bioengineered/biologic RNA agents produced through fermentation and their potential applications to RNA research and drug development.

Citing Articles

Design and testing of Hepatitis Delta Ribozymes for suppression of Chikungunya virus infection in cell cultures.

Fraser M, Kucharski C, Loh Z, Hanahoe E, Fraser Jr M Med Res Arch. 2024; 12(8).

PMID: 39324067 PMC: 11423935. DOI: 10.18103/mra.v12i8.5762.


Efflux ABC transporters in drug disposition and their posttranscriptional gene regulation by microRNAs.

Wang Y, Tu M, Yu A Front Pharmacol. 2024; 15:1423416.

PMID: 39114355 PMC: 11303158. DOI: 10.3389/fphar.2024.1423416.


Molecular Engineering of Functional SiRNA Agents.

Batra N, Tu M, Yu A ACS Synth Biol. 2024; 13(6):1906-1915.

PMID: 38733599 PMC: 11197084. DOI: 10.1021/acssynbio.4c00181.


tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription.

Xiong Q, Zhang Y, Xu Y, Yang Y, Zhang Z, Zhou Y Oncogene. 2024; 43(17):1274-1287.

PMID: 38443680 PMC: 11035144. DOI: 10.1038/s41388-024-02991-9.


Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents.

Traber G, Yi C, Batra N, Tu M, Yu A RNA. 2024; 30(6):680-694.

PMID: 38429100 PMC: 11098458. DOI: 10.1261/rna.079904.123.


References
1.
Jian C, Tu M, Ho P, Duan Z, Zhang Q, Qiu J . Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget. 2017; 8(19):30742-30755. PMC: 5458164. DOI: 10.18632/oncotarget.16372. View

2.
Winkler J . Oligonucleotide conjugates for therapeutic applications. Ther Deliv. 2013; 4(7):791-809. PMC: 3787477. DOI: 10.4155/tde.13.47. View

3.
Li M, Wang W, Wu W, Huang M, Yu A . Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. Drug Metab Dispos. 2014; 42(11):1791-5. PMC: 4201134. DOI: 10.1124/dmd.114.060145. View

4.
Chen X, Mangala L, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood A . RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2017; 37(1):107-124. PMC: 5898634. DOI: 10.1007/s10555-017-9717-6. View

5.
Zhang F, Wen Y, Guo X . CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014; 23(R1):R40-6. DOI: 10.1093/hmg/ddu125. View